StemGenex continues to announce groundbreaking stem cell therapies for MS patients(03/12/13)

New targeted stem cell therapy looks to improve MS patients dealing with incontinence complications.

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the newest therapy to assist patients diagnosed with Multiple Sclerosis.

According to the National MS Society, at least 80% of people with MS experience bladder dysfunction. StemGenex believes a new therapy delivering adipose derived mesenchymal cells directly to the bladder may reduce the inflammation that is causing the patients incontinence.

Direct bladder targeting is the latest in a series of targeted therapies StemGenex plans to announce in the next few months for patients dealing with degenerative diseases such as Parkinsons, Alzheimers, COPD and of course Multiple Sclerosis. Earlier this month StemGenex announced a new intranasal stem cell therapy. The goal of this new technique is to encourage more stem cells to travel through the blood brain barrier to target the damage caused by MS.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others. Rita Alexander, founder of StemGenex and the companys first stem cell patient, insists that all patients be treated like they are one of our loved ones. "Hope, compassion, and the relentless pursuit for an end to these diseases are our primary focus."

Source: Copyright 1997-2013, Vocus PRW Holdings, LLC. Vocus, PRWeb (03/12/13)

A team of Ottawa doctors is preparing to publish a full report on its breakthrough multiple sclerosis treatment study that has so far eliminated the disease in those treated.

The experimental study began about 13 years ago as a last resort for patients who fail to improve on drug therapy and who suffer severe symptoms of MS. Snippets of the results have been published here and there, said, neurologist Dr. Mark Freedman, one of the leads of the program at The Ottawa Hospital, but its never been published in its entirety.

No specific date has been set for its release, but the teams findings are far from secret. With MS not returning in any of the 24 participants, patient success stories appear in news media across the country. Since the original studys completion, about another dozen patients have been treated with all of them showing the same results.

Go here to see the original:
MS-UK | Stem cells And MS Research